Detalles de la búsqueda
1.
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma.
Curr Opin Oncol
; 35(2): 100-106, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36700456
2.
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
J Transl Med
; 20(1): 419, 2022 09 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36089578
3.
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
J Transl Med
; 19(1): 232, 2021 05 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-34059094
4.
Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants.
HLA
; 99(4): 313-327, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35073457
5.
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
J Immunother Cancer
; 10(5)2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35613827
6.
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.
Front Immunol
; 12: 682492, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34290704
7.
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Front Immunol
; 12: 663865, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34046035
Resultados
1 -
7
de 7
1
Próxima >
>>